{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:35:15Z","timestamp":1793104515073,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Teikoku Seiyaku Co., Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jdermsci.2019.05.008","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T10:30:57Z","timestamp":1559385057000},"page":"339-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Long-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: A 12-month, multicenter, open-label clinical trial"],"prefix":"10.1016","volume":"94","author":[{"given":"Michihiro","family":"Hide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jdermsci.2019.05.008_bib0005","first-page":"1339","article-title":"Guidelines for the diagnosis and treatment of urticaria","volume":"121","author":"Hide","year":"2011","journal-title":"Nihon Hifukagakkai Zasshi [Jpn. J. Dermatol.]"},{"key":"10.1016\/j.jdermsci.2019.05.008_bib0010","series-title":"Today\u2019s Therapy in Dermatology","year":"2012"},{"issue":"2","key":"10.1016\/j.jdermsci.2019.05.008_bib0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1083\/jcb.201603042","article-title":"The cell biology of acute itch","volume":"213","author":"Green","year":"2016","journal-title":"J. Cell Biol."},{"issue":"2","key":"10.1016\/j.jdermsci.2019.05.008_bib0020","first-page":"121","article-title":"Guidelines for the diagnosis and treatment of atopic dermatitis 2016","volume":"126","author":"Katoh","year":"2016","journal-title":"Nihon Hifukagakkai Zasshi [Jpn. J. Dermatol.]"},{"issue":"9","key":"10.1016\/j.jdermsci.2019.05.008_bib0025","first-page":"1757","article-title":"Guidelines for the diagnosis and treatment of contact dermatitis","volume":"119","author":"Takayama","year":"2009","journal-title":"Nihon Hifukagakkai Zasshi [Jpn. J. Dermatol.]"},{"issue":"2","key":"10.1016\/j.jdermsci.2019.05.008_bib0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5021\/ad.2010.22.2.125","article-title":"Atopic dermatitis","volume":"22","author":"Bieber","year":"2010","journal-title":"Ann. Dermatol."},{"issue":"2","key":"10.1016\/j.jdermsci.2019.05.008_bib0035","first-page":"267","article-title":"Guidelines for the diagnosis and treatment of generalized pruritus","volume":"122","author":"Sato","year":"2012","journal-title":"Nihon Hifukagakkai Zasshi [Jpn. J. Dermatol.]"},{"issue":"suppl 3","key":"10.1016\/j.jdermsci.2019.05.008_bib0040","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2222.1999.0290s3147.x","article-title":"Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation","volume":"29","author":"Kay","year":"1999","journal-title":"Clin. Exp. Allergy"},{"issue":"11","key":"10.1016\/j.jdermsci.2019.05.008_bib0045","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1021\/jm00043a009","article-title":"[(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine","volume":"37","author":"Carceller","year":"1994","journal-title":"J. Med. Chem."},{"issue":"5 Pt 1","key":"10.1016\/j.jdermsci.2019.05.008_bib0050","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0091-6749(88)90952-9","article-title":"Platelet-activating factor as a mediator of allergic disease","volume":"81","author":"Barnes","year":"1988","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jdermsci.2019.05.008_bib0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.alit.2018.06.002","article-title":"Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: a double-blind, randomized, multicenter, placebo-controlled clinical trial","volume":"68","author":"Hide","year":"2019","journal-title":"Allergol. Int."},{"issue":"20","key":"10.1016\/j.jdermsci.2019.05.008_bib0060","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"J.A.M.A."},{"key":"10.1016\/j.jdermsci.2019.05.008_bib0065","series-title":"Medical Dictionary for Regulatory Activities","year":"2015"},{"key":"10.1016\/j.jdermsci.2019.05.008_bib0070","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","author":"National Cancer Institute","year":"2018"},{"issue":"1","key":"10.1016\/j.jdermsci.2019.05.008_bib0075","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2340\/00015555-2150","article-title":"Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria","volume":"96","author":"Abajian","year":"2016","journal-title":"Acta. Derm. Venereol."},{"issue":"6","key":"10.1016\/j.jdermsci.2019.05.008_bib0080","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.1365-2133.2010.10029.x","article-title":"Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males","volume":"163","author":"Church","year":"2010","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.jdermsci.2019.05.008_bib0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40629-014-0011-7","article-title":"Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects","volume":"23","author":"Shamizadeh","year":"2014","journal-title":"Allergo. J. Int."},{"issue":"5","key":"10.1016\/j.jdermsci.2019.05.008_bib0090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4155\/cli.14.26","article-title":"Rupatadine for the treatment of allergic rhinitis and urticaria: a look at the clinical data","volume":"4","author":"Ridolo","year":"2014","journal-title":"Clin. Invest."},{"issue":"6","key":"10.1016\/j.jdermsci.2019.05.008_bib0095","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1046\/j.1365-2133.2003.05293.x","article-title":"Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study","volume":"148","author":"Kawashima","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2019.05.008_bib0100","first-page":"661","article-title":"[A study of the effect on itch and quality of life of atopic dermatitis patients treated by standard therapy with anti-allergic drug], rinsho hifu ka","volume":"60","author":"Kawashima","year":"2006","journal-title":"Jpn. J. Clin. Dermatol."},{"key":"10.1016\/j.jdermsci.2019.05.008_bib0105","first-page":"1105","article-title":"[Investigation of the clinical efficacy of loratadine (claritin tablets) for pruritus associated with atopic dermatitis]","volume":"24","author":"Hashizume","year":"2004","journal-title":"Arerugi No Rinsho [Allergy Pract.]"},{"issue":"6","key":"10.1016\/j.jdermsci.2019.05.008_bib0110","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2340\/0001555577449451","article-title":"Topical application of a platelet-activating factor (PAF) antagonist in atopic dermatitis","volume":"77","author":"Abeck","year":"1997","journal-title":"Acta Derm. Venereol."},{"issue":"9","key":"10.1016\/j.jdermsci.2019.05.008_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163020","article-title":"Pharmacokinetics, safety and cognitive function profile of rupatadine 10, 20 and 40 mg in healthy Japanese subjects: a randomised placebo-controlled trial","volume":"11","author":"T\u00e4ubel","year":"2016","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.jdermsci.2019.05.008_bib0120","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hup.856","article-title":"Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers","volume":"22","author":"Vuurman","year":"2007","journal-title":"Hum. Psychopharmacol."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092318111930146X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092318111930146X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:49:55Z","timestamp":1760330995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092318111930146X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S092318111930146X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2019.05.008","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: A 12-month, multicenter, open-label clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2019.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}